TEST EARLY AND COMPREHENSIVELY TO UNCOVER ACTIONABLE ONCOGENIC DRIVERS, INCLUDING NTRKa GENE FUSIONS
Test for NTRK gene fusions as part of your broad molecular testing1,2
NGSa allows for efficient multiplex testing, with the ability to find NTRK gene fusions as well as other key oncogenic drivers.
FDAa-approved NTRK gene fusion companion diagnostic test3
Select patients for treatment with VITRAKVI® (larotrectinib) based on the presence of an NTRK gene fusion in tumor specimens, as determined by an FDA-approved test. Information on FDA-approved tests is available at http://www.fda.gov/companiondiagnostics